Abstract:<h3> Objectives</h3><p>To report on the routine clinical implementation of cell‐free DNA (cfDNA) analysis of maternal blood for trisomies 21, 18 and 13 in twin pregnancy and to define the performance of the test by combining our results with those identified in a systematic review of the literature.</p><h3> Methods</h3><p>The data for the prospective study were derived from screening for trisomies 21, 18 and 13 in twin pregnancies at 10 + 0 to 14 + 1 weeks' gestation. Two populations were included; first, self‐referred women to the Fetal Medicine Centre in London or Brugmann University Hospital in Brussels and, second, women selected for the cfDNA test after routine first‐trimester combined testing at one of two National Health Service hospitals in England. This dataset was used to determine the performance of screening for the three trisomies. Search of MEDLINE, EMBASE, CENTRAL (The Cochrane Library), <a href="http://clinicaltrials.gov">ClinicalTrials.gov</a> and the World Health Organization International Clinical Trials Registry Platform (ICTRP) was carried out to identify all peer‐reviewed publications on clinical validation or implementation of maternal cfDNA testing for trisomies 21, 18 and 13 in twin pregnancy. A meta‐analysis was then performed using our data and those in the studies identified by the literature search. </p><h3> Results</h3><p>In our dataset of 997 twin pregnancies with a cfDNA result and known outcome, the test classified correctly 16 (94.1%) of the 17 cases of trisomy 21, nine (90.0%) of the 10 cases of trisomy 18, one (50.0%) of the two cases of trisomy 13 and 962 (99.4%) of the 968 cases without any of the three trisomies. The literature search identified seven relevant studies, excluding our previous papers because their data are included in the current study. In the combined populations of our study and the seven studies identified by the literature search, there were 56 trisomy‐21 and 3718 non‐trisomy‐21 twin pregnancies; the pooled weighted detection rate (DR) and false‐positive rate (FPR) were 98.2% (95% CI, 83.2–99.8%) and 0.05% (95% CI, 0.01–0.26%), respectively. In the combined total of 18 cases of trisomy 18 and 3143 non‐trisomy‐18 pregnancies, the pooled weighted DR and FPR were 88.9% (95% CI, 64.8–97.2%) and 0.03% (95% CI, 0.00–0.33%), respectively. For trisomy 13, there were only three affected cases and two (66.7%) of these were detected by the cfDNA test at a FPR of 0.19% (5/2569).</p><h3> Conclusions</h3><p>The performance of cfDNA testing for trisomy 21 in twin pregnancy is similar to that reported in singleton pregnancy and is superior to that of the first‐trimester combined test or second‐trimester biochemical testing. The number of cases of trisomies 18 and 13 is too small for accurate assessment of the predictive performance of the cfDNA test. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.</p>

[First-trimester screening for trisomies 18 and 13 with the combined use of the risk algorithms for trisomy 21, 18 and 13]

Predictive Significance of Risk Value in Prenatal Screening for Fetal Trisomy 18

Noninvasive Prenatal Testing of Trisomies 21 and 18 by Massively Parallel Sequencing of Maternal Plasma DNA in Twin Pregnancies.

Clinical application of noninvasive prenatal testing for the detection of trisomies 21, 18, and 13: a hospital experience.

Comparison of three first trimester screening algorithms for trisomy 21 with and without adjustment for maternal characteristics

First-trimester risk calculation for trisomy 13, 18, and 21: comparison of the screening efficiency between 2 locally developed programs and commercial software

The Value of Combined Detailed First-Trimester Ultrasound–biochemical Analysis for Screening Fetal Aneuploidy in the Era of Non-Invasive Prenatal Testing

Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta‐analysis

Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks

Diagnostic value of maternal alpha-fetoprotein variants in second-trimester biochemical screening for trisomy 21 and 18

Maternal Prenatal Screening Programs That Predict Trisomy 21, Trisomy 18, and Neural Tube Defects in Offspring

First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A

A Risk Model for Predicting Fetuses with Trisomy 21 Using Alpha-Fetoprotein Variants L2 Combined with Maternal Serum Biomarkers in Early Pregnancy

Serum marker truncation limits in first trimester antenatal screening for trisomy 18

Clinical Efficiency of Non-invasive Prenatal Screening for Common Trisomies in Low-Risk and Twin Pregnancies

Non-invasive Prenatal Testing for Trisomies 21, 18 and 13: Clinical Experience from 146,958 Pregnancies.

A retrospective evaluation of second-trimester serum screening for fetal trisomy 18: experience of two laboratories

Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening

Importance of a detailed anomaly scan after a cfDNA test indicating fetal trisomy 21, 18 or 13

Comparison of triple-risk assessment of fetal trisomy 21 including total human choriogonadotropin (hCG) or its free beta-subunit (free beta hCG)

Performance of Non-Invasive Prenatal Testing for Trisomies 21 and 18 in Twin Pregnancies.